- Home
- FPI vs ATXS Comparison
FPI vs ATXS Comparison
Compare FPI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPI
- ATXS
- Stock Information
- Founded
- FPI 2013
- ATXS 2008
- Country
- FPI United States
- ATXS United States
- Employees
- FPI N/A
- ATXS N/A
- Industry
- FPI Real Estate Investment Trusts
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- FPI Real Estate
- ATXS Health Care
- Exchange
- FPI Nasdaq
- ATXS Nasdaq
- Market Cap
- FPI 478.7M
- ATXS 424.4M
- IPO Year
- FPI 2014
- ATXS 2015
- Fundamental
- Price
- FPI $10.98
- ATXS $7.51
- Analyst Decision
- FPI
- ATXS Buy
- Analyst Count
- FPI 0
- ATXS 6
- Target Price
- FPI N/A
- ATXS $32.00
- AVG Volume (30 Days)
- FPI 300.6K
- ATXS 318.8K
- Earning Date
- FPI 10-29-2025
- ATXS 08-12-2025
- Dividend Yield
- FPI 2.20%
- ATXS N/A
- EPS Growth
- FPI 229.01
- ATXS N/A
- EPS
- FPI 1.21
- ATXS N/A
- Revenue
- FPI $55,000,000.00
- ATXS N/A
- Revenue This Year
- FPI N/A
- ATXS N/A
- Revenue Next Year
- FPI N/A
- ATXS N/A
- P/E Ratio
- FPI $9.04
- ATXS N/A
- Revenue Growth
- FPI N/A
- ATXS N/A
- 52 Week Low
- FPI $9.66
- ATXS $3.56
- 52 Week High
- FPI $12.87
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- FPI 54.19
- ATXS 60.14
- Support Level
- FPI $10.60
- ATXS $7.12
- Resistance Level
- FPI $10.79
- ATXS $7.91
- Average True Range (ATR)
- FPI 0.17
- ATXS 0.46
- MACD
- FPI 0.01
- ATXS 0.10
- Stochastic Oscillator
- FPI 73.55
- ATXS 77.51
About FPI Farmland Partners Inc.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.